Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Stephen A. Farkas"'
Publikováno v:
Current Therapeutic Research. 58:903-916
This multicenter, open-label, randomized clinical trial compared the efficacy and tolerability of intravenous (IV) meropenem 0.5 g every 8 hours (n = 147) and IV ceftazidime 1 g every 8 hours (n = 148) as empiric monotherapy for 295 patients hospital
Publikováno v:
Critical Care Medicine. 25:1663-1670
Objective To evaluate the efficacy and tolerability of intravenous empiric treatment with meropenem compared with ceftazidimetobramycin in patients with hospital-acquired lower respiratory tract infections.Design Prospective, nonblind, randomized tri
Autor:
Stephen A. Farkas
Publikováno v:
The American Journal of Medicine. 94:142S-149S
Fleroxacin, administered intravenously at a dosage of 400 mg once a day, was compared with ceftazidime, 0.5-2 g three times daily or 1-2 g twice daily, administered for 4-21 days, for treatment of nonpneumococcal lower respiratory tract infections. A
Autor:
Stan A. Greene, Robert McCabe, Valerie Chirurgi, George Heinz, Stephen A. Farkas, Alastair Haddow
Publikováno v:
The American journal of medicine. 100(6A)
Patients with bacterial pneumonia often are treated empirically with parenteral broad-spectrum antimicrobials intended to cover potential gram-negative and gram-positive pathogens. However, beta-lactamase-mediated resistance has developed to many of
Publikováno v:
American Journal of Obstetrics and Gynecology. 163:138-139
A case of necrotizing fasciitis with full-thickness loss of the entire abdominal wall is reported after an uncomplicated sterilization by bilateral partial salpingectomy through a minilaparotomy incision in a healthy young patient. Salvage was accomp